CLINICAL AND IMMUNOLOGICAL SIGNIFICANCE OF CALPROTECTIN IN ULCERATIVE COLITIS
Abstract
Ulcerative colitis (UC) is a chronic inflammatory disease of the colon characterized by inflammation and ulceration of the mucosal layer. The disease follows a relapsing clinical course with periods of remission. Non-invasive, accurate, and cost-effective biomarkers are essential for assessing disease activity and monitoring treatment efficacy.
References
1. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005;54(3):364-368.
2. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105(1):162-169.
3. Lin JF, Chen JM, Zuo JH, et al. Meta-analysis: Fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis. 2014;20(8):1407-1415.
4. D'Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(12):2218-2224.
5. Mao R, Xiao YL, Gao X, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis. 2012;18(10):1894-1899.
